Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00482508
First received: June 4, 2007
Last updated: October 24, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2005
  Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)